RMRebecca Moeller

Rebecca Moeller

*This is an algorithmically generated author record based on publicly available information.

Rebecca Moeller has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Antonia P. Gunesch

    Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany

    1 shared publication
  • Dominic Wichmann

    University Medical Center Hamburg-Eppendorf, Department of Intensive Care Medicine, Hamburg, Germany

    1 shared publication
  • Francisco José Zapatero Belinchón

    Gladstone Institute of Virology, Gladstone Institutes

    1 shared publication
  • Gisa Gerold

    Umeå University

    1 shared publication
  • Graham Brogden

    Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany

    1 shared publication
  • Jared Kirui

    Institute for Experimental Virology, TWINCORE, Centre for Experimental and Clinical Infection Research, a joint venture between the Medical School Hannover and the Helmholtz Centre for Infection Research, Hannover, Germany

    1 shared publication

Latest Publications

  • Open Access

    Effect of statins on SARS-CoV-2 infection

    by Rebecca Moeller, Francisco J. Zapatero-Belinchón, Lisa Lasswitz, Jared Kirui, Graham Brogden, Antonia P. Gunesch, Thomas Pietschmann, Dominic Wichmann, Stefan Kluge, Gisa Gerold

    The retrospective analysis of clinical data of patients suffering from COVID-19 has indicated that statin therapy, used to lower plasma cholesterol levels, is associated with a better clinical outcome. We therefore investigated the effect of statins on SARS-CoV-2 infection and found that selective statins reduced SARS-CoV-2 cell entry and inhibited high and low pathogenic coronavirus infection in human cells. A retrospective study on hospitalized patients with COVID-19 implies that reduced high density lipoprotein levels, which are typically counteracted by statin therapy, are associated with aggravated disease outcome. These results suggest that statin therapy poses no additional risk to individuals exposed to SARS-CoV-2 and that some statins may have a mild beneficial effect on COVID-19 outcome. Placebo controlled trials are required to clarify the role of statins in COVID-19 infected patients .